PLX
Price:
$1.73
Market Cap:
$127.39M
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in the last stage of clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis...[Read more]
Industry
Biotechnology
IPO Date
1998-05-15
Stock Exchange
AMEX
Ticker
PLX
According to Protalix BioTherapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is -30.89%. This represents a change of 296.55% compared to the average of -7.79% of the last 4 quarters.
The mean historical ROE of Protalix BioTherapeutics, Inc. over the last ten years is 202.56%. The current -30.89% ROE has changed -115.25% with respect to the historical average. Over the past ten years (40 quarters), PLX's ROE was at its highest in in the December 2015 quarter at 670.47%. The ROE was at its lowest in in the September 2021 quarter at -1971.36%.
Average
202.56%
Median
97.69%
Minimum
24.76%
Maximum
563.04%
Discovering the peaks and valleys of Protalix BioTherapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 922.22%
Maximum Annual ROE = 563.04%
Minimum Annual Increase = -82.35%
Minimum Annual ROE = 24.76%
Year | ROE | Change |
---|---|---|
2023 | 24.76% | -82.35% |
2022 | 140.29% | -75.08% |
2021 | 563.04% | 922.22% |
2020 | 55.08% | 47.60% |
2019 | 37.32% | -25.41% |
2018 | 50.03% | -81.64% |
2017 | 272.51% | -7.60% |
2016 | 294.92% | -44.75% |
2015 | 533.77% | 891.16% |
2014 | 53.85% | -47.78% |
The current ROE of Protalix BioTherapeutics, Inc. (PLX) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
242.70%
5-year avg
164.10%
10-year avg
202.56%
Protalix BioTherapeutics, Inc.’s ROE is greater than Corvus Pharmaceuticals, Inc. (-167.55%), greater than Aldeyra Therapeutics, Inc. (-43.01%), less than Gamida Cell Ltd. (187.96%), less than Checkpoint Therapeutics, Inc. (359.97%), greater than Cidara Therapeutics, Inc. (-219.21%), less than Akebia Therapeutics, Inc. (129.56%), greater than X4 Pharmaceuticals, Inc. (-32.51%), less than Seres Therapeutics, Inc. (60.75%), less than eFFECTOR Therapeutics, Inc. (2.18%), greater than PDS Biotechnology Corporation (-139.57%), greater than aTyr Pharma, Inc. (-56.83%), greater than Elevation Oncology, Inc. (-59.73%), less than Lexicon Pharmaceuticals, Inc. (0%), greater than Iovance Biotherapeutics, Inc. (-107.38%), greater than ImmunoGen, Inc. (-58.43%), less than null (5.04%),
Company | ROE | Market cap |
---|---|---|
-167.55% | $292.37M | |
-43.01% | $285.24M | |
187.96% | $4.34M | |
359.97% | $170.39M | |
-219.21% | $164.89M | |
129.56% | $403.63M | |
-32.51% | $98.42M | |
60.75% | $164.78M | |
2.18% | $941.00 | |
-139.57% | $62.47M | |
-56.83% | $131.12M | |
-59.73% | $33.90M | |
0% | $298.95M | |
-107.38% | $2.27B | |
-58.43% | $8.73B | |
5.04% | $0 |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Protalix BioTherapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Protalix BioTherapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Protalix BioTherapeutics, Inc.'s ROE?
How is the ROE calculated for Protalix BioTherapeutics, Inc. (PLX)?
What is the highest ROE for Protalix BioTherapeutics, Inc. (PLX)?
What is the 3-year average ROE for Protalix BioTherapeutics, Inc. (PLX)?
What is the 5-year average ROE for Protalix BioTherapeutics, Inc. (PLX)?
How does the current ROE for Protalix BioTherapeutics, Inc. (PLX) compare to its historical average?